NCT06271252 - A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 3, 2024

Primary Completion Date

December 12, 2026

Study Completion Date

April 12, 2028

Conditions

Neoplasms, Plasma CellNeoplasms by Histologic TypeNeoplasmsHemostatic DisordersVascular DiseasesCardiovascular DiseasesParaproteinemiasBlood Protein DisordersHematologic DiseasesHemorrhagic DisordersLymphoproliferative DisordersImmunoproliferative DisordersImmune System DiseasesMultiple Myeloma

Interventions

DRUG

OriCAR-017

Anti-GPRC5D CAR-T cell product

Trial Locations (1)

30342

RECRUITING

Northside Hospital, Atlanta